Mitragyna speciosa (Kratom)

Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia whose leaves contain mitragynine and 7-hydroxymitragynine alkaloids that interact with opioid receptors. These compounds produce dose-dependent effects ranging from stimulation at low doses to sedation at higher doses.

Origin & History

Mitragyna speciosa (kratom) is a tropical evergreen tree in the Rubiaceae family native to Southeast Asia, particularly Thailand, Malaysia, Indonesia, and Papua New Guinea, where its leaves are harvested as the primary source. The leaves are typically dried and powdered, with alkaloids extracted using accelerated solvent extraction at 60°C yielding 0.53–2.91 g dry extract with mitragynine content of 1.83–7.19%.

Historical & Cultural Context

Kratom leaves have been used in Southeast Asian traditional medicine systems, including Thai and Malaysian folk practices, for centuries. The leaves are often prepared as water decoctions for their pharmacological properties, though specific traditional indications and duration of use are not detailed in available research.

Health Benefits

• Traditional use for pharmacological properties in Southeast Asian medicine (evidence quality: traditional use only)
• Contains mitragynine alkaloid with potential bioactivity (evidence quality: chemical characterization only)
• Water decoctions used in Thai and Malaysian folk practices (evidence quality: traditional use only)
• Various extraction methods yield different alkaloid concentrations (evidence quality: in vitro studies)
• Limited clinical evidence available for specific health claims (evidence quality: insufficient)

How It Works

Kratom's primary alkaloids mitragynine and 7-hydroxymitragynine bind to mu-opioid receptors as partial agonists, providing analgesic effects without full opioid receptor activation. These compounds also interact with alpha-2 adrenergic receptors and serotonin receptors, contributing to mood and energy effects. At low doses, noradrenergic and serotonergic pathways predominate, while higher doses favor opioidergic activity.

Scientific Research

The research dossier reveals a significant gap in clinical evidence, with no human clinical trials, RCTs, or meta-analyses identified for Mitragyna speciosa. Available data focus solely on in vitro evaluations examining kratom extracts (0–128 μg/mL) and alkaloids (0–128 μM) on CES1 enzyme activity, without any human outcome measures or PMIDs for clinical studies provided.

Clinical Summary

Most kratom research consists of animal studies and case reports rather than controlled human trials. A 2019 survey study of 2,798 kratom users reported self-reported benefits for pain, anxiety, and opioid withdrawal symptoms. Limited pharmacokinetic studies show mitragynine plasma levels peak 1-2 hours after oral administration. The FDA has not approved kratom for any medical condition, and controlled clinical trials are lacking to establish safety and efficacy.

Nutritional Profile

{"macronutrients": {"protein": "Low, approximately 1-2% by weight", "fiber": "Moderate, approximately 5-7% by weight"}, "micronutrients": {"vitamins": {"Vitamin C": "Trace amounts, less than 1% of daily value per serving"}, "minerals": {"Calcium": "Approximately 0.1% by weight", "Magnesium": "Approximately 0.2% by weight", "Potassium": "Approximately 1% by weight"}}, "bioactive_compounds": {"Mitragynine": "Approximately 0.5-1.5% by weight", "7-Hydroxymitragynine": "Less than 0.05% by weight", "Speciociliatine": "Approximately 0.1% by weight", "Paynantheine": "Approximately 0.1% by weight"}, "bioavailability_notes": "Bioactive alkaloids such as mitragynine are believed to have moderate oral bioavailability, but precise absorption rates are not well-documented. Nutrient absorption may vary based on preparation and individual digestive factors."}

Preparation & Dosage

No clinically studied dosage ranges are available from human trials. Extraction studies report mitragynine yields of 1.54–1.83% from water extraction and up to 7.19% from methanol extraction, but these lack standardization or clinical dosing context. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient data for evidence-based combinations

Safety & Interactions

Kratom can cause nausea, constipation, dry mouth, and dependence with regular use. It may interact with cytochrome P450 enzymes, potentially affecting metabolism of other medications including antidepressants and blood thinners. The DEA considers kratom a "drug of concern" due to abuse potential and reported deaths in combination with other substances. Pregnant and breastfeeding women should avoid kratom due to unknown fetal effects and potential withdrawal in newborns.